ClinicalTrials.gg
No longer availableNCT05095116Updated Oct 3, 2025

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

An expanded access record providing APT-1011 3 mg HS in Eosinophilic Esophagitis, sponsored by Ellodi Pharmaceuticals, LP. No longer available at 35 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Ellodi Pharmaceuticals, LP · Expanded access

Study type
Expanded access
Access type
Intermediate-size population
Ages
12 Years and older
Sex
All
01

Study summary

This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.

Read the detailed description

Patients will receive a 120-day supply of APT-1011 and will attend scheduled clinic visits every 4 months. Telephone visits will be performed as needed. At each clinic visit (or additional telephone visit), adverse events (AEs) and concomitant medications will be collected. The Global EoE score will be collected at clinic visits.

02

Conditions studied

  • Eosinophilic Esophagitis

Keywords

  • APT-1011
  • Esophagitis
  • Eosinophilic Esophagitis
  • Esophageal Diseases
  • Gastrointestinal Diseases
  • Gastroenteritis
  • Eosinophilia
  • Leukocyte Disorders
  • Hematologic Diseases
  • Hypersensitivity, Immediate
  • Hypersensitivity
  • Immune System Diseases
  • Fluticasone
  • Anti-Inflammatory Agents
  • Bronchodilator Agents
  • Autonomic Agents
  • Peripheral Nervous System Agents
  • Anti-Asthmatic Agents
  • Respiratory System Agents
  • Anti-Allergic Agents
03

In context

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Lead sponsor

Ellodi Pharmaceuticals, LP is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥12 years of age at the time of
  2. Signed ICF and willing and able to adhere to all procedures; signed assent form and parent/guardian ICF must also be collected for adolescents
  3. Confirmed medical history of EoE
  4. Adult and adolescent patients who are unable or ineligible to enroll in an APT-1011 clinical study or have failed available treatment options
  5. Willing and able to adhere to the treatment regimen and visit schedule

Exclusion criteria

Exclusion Criteria:

  1. Have known , , or intolerance to
  2. Have signs and symptoms of adrenal suppression or hypercorticism
  3. Use of potent inhibitors (e.g., ritonavir and ketoconazole) are prohibited
  4. Have current alcohol or drug abuse in the opinion of the Investigator
  5. Female patients who are pregnant, breastfeeding, or planning to become pregnant while participating in the program
  6. Female patients of who are unable to comply with adequate use during the program
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.

    Also known as: fluticasone propionate

06

Where to request access

35 sites
  • Del Sol Research Management LLC
    Tucson, Arizona 85715, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Ventura County Gastroenterology Medical Group Camarillo
    Camarillo, California 93012, United States
  • FOMAT Medical Research
    Glendale, California 91204, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Western States Clinical Research Inc
    Wheat Ridge, Colorado 80033, United States
  • Nuvance Health Medical Practice Ct, Inc.
    Danbury, Connecticut 06810, United States
  • Medical Research Center of Connecticut
    Hamden, Connecticut 06518-3694, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Endoscopic Research, Inc.
    Orlando, Florida 32803, United States
  • Summit Clinical Research
    Athens, Georgia 30607, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • MGG Group Co., Inc.
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Boston Specialists
    Boston, Massachusetts 02111, United States
  • Clinical Research Institute of Michigan LLC
    Chesterfield, Michigan 48047, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • West Michigan Clinical Research Center
    Wyoming, Michigan 49519, United States
  • MNGI Digestive Health, P.A.
    Minneapolis, Minnesota 55413, United States
  • Minnesota Gastroenterology PA Plymouth Endoscopy Center Clinic
    Plymouth, Minnesota 55446, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Bozeman Health Clinical Research
    Bozeman, Montana 59715, United States
  • Clinical and Translational Research Center (CTRC)
    Chapel Hill, North Carolina 27599, United States
  • Carolina Research
    Greenville, North Carolina 27834, United States
  • Gastro Health Research
    Cincinnati, Ohio 45219, United States
  • Bernstein Clinical Research Center, LLC
    Cincinnati, Ohio 45236, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Northshore Gastroenterology Research LLC
    Westlake, Ohio 44145, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Regional Gastroenterology Associates of Lancaster, Ltd.
    Wyomissing, Pennsylvania 19610, United States
  • Rapid City Medical Center LLP
    Rapid City, South Dakota 57701, United States
  • GI Alliance
    Garland, Texas 75044, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT05095116
Lead sponsor
Ellodi Pharmaceuticals, LP
Responsible party
Sponsor
First posted
Oct 27, 2021
Last update
Oct 3, 2025
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion